

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DeRobertis et al.	Examiner:	Romeo, D.
Serial No.	Not yet assigned	Group Art Unit:	1647
Filed:	April 21, 2000	Docket No.	510015-261
Title:	ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – OLIGONUCLEOTIDES FOR EXPRESSING HUMAN FRAZZLED (FRZB-1) PROTEIN		

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL585707643US

Date of Deposit: July 11, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Amber Stewart

PRELIMINARY AMENDMENT

BOX: Patent Application
Commissioner for Patents
Washington, D.C. 20231

Sir:

IN THE TITLE

Please amend the title to read "ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – OLIGONUCLEOTIDES FOR EXPRESSING HUMAN FRAZZLED (FRZB-1) PROTEIN".

IN THE SPECIFICATION

1. The following shows the changes made to the paragraph originally found at page 1, line 14 of the specification:

This application is a Divisional of Application Serial No. 09/552,988 filed April 21, 2000, which claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.

IN THE CLAIMS

Please cancel claim 1 and amend claims as follows:

9. (Amended) An oligonucleotide construct comprising a sequence coding for a protein and an expression vector operatively linked therewith, the protein being expressible from SEQ ID NO:10.

10. The construct as in claim 9 wherein the protein is expressible in soluble form.

11. The construct as in claim 9 wherein the expression vector is a mammalian or viral expression vector.

IN THE SPECIFICATION

At page 1, at line 14, please delete: "This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996." And insert therefore: --This application is a Divisional Application of application Ser. No. 09/552,988 filed April 21, 2000, which claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.--

REMARKS


In compliance with the requirements of 37 CFR 1.821-1.825, the Applicant encloses a computer readable form copy of the Sequence Listings referred to in the application. The Applicant submits that the content of the paper copy of the Sequence Listing and computer readable copies are the same, thus the computer readable form copy of the Sequence Listings no new matter has been added to the application.

Consideration of the above application is respectfully requested.

In view of the above, it is submitted that this application is in good order for allowance, and such early action is respectfully solicited. Should matters remain which the Examiner

believes could be resolved in a telephone interview, the Examiner is requested to telephone the Applicant's undersigned attorney.

Respectfully submitted,



Charles Berman

Reg. No. 29,249

Date: July 11, 2001

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5000
FAX: (310) 788-5100

ADDENDUM PAGES

VERSION MARKED TO REFLECT CHANGES

I. CHANGES IN THE TITLE

Please amend the title to read “ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – OLIGONUCLEOTIDES FOR EXPRESSING HUMAN FRAZZLED (FRZB-1) PROTEIN”.

II. CHANGES IN SPECIFICATION

1. The following shows the changes made to the paragraph originally found at page 1, line 14 of the specification:

[This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.] This application is a Divisional of Application Serial No. 09/552,988 filed April 21, 2000, which claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.

III. CHANGES IN THE CLAIMS

9. (Amended) An oligonucleotide construct comprising a sequence coding for a protein and an expression vector operatively linked therewith, the protein being expressible from [SEQ ID NO:4, SEQ ID NO:8 or] SEQ ID NO:10.

10. The construct as in claim 9 wherein the protein is expressible in soluble form.

11. The construct as in claim 9 wherein the expression vector is a mammalian or viral expression vector.